Syneos – Q4 2022 Performance Expectations, Competitive Positioning & Potential Acquisition Target

  • Credit
  • Healthcare
  • North America


Former EVP at Syneos Health Inc


  • Near-term portfolio capitalisation opportunities for Syneos (NASDAQ: SYNH) within the DCT (decentralised clinical trial), data analysis and remote monitoring spaces
  • Syneos’s strengths and weaknesses vs other CROs (contract research organisations) such as Iqvia (NYSE: IQV), Icon (NASDAQ: ICLR), PPD (NASDAQ: PPD) and Covance (NYSE: LH), highlighting key therapeutic growth drivers in clinical and commercial segments
  • Q4 2022 performance expectations, discussing new business wins, expected book-to-bill ratio, staffing and client retention ability
  • Potential acquisition of Syneos and possible near-term consolidation strategy post financial deterioration
  • 6-12-month company outlook under new CEO and CFO, given deceleration of invested capital in biotech


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited